A Phase III Study of atezolizumab in Combination With Carboplatin or Cisplatin + Pemetrexed in Patients With Stage IV Non-squamous Non-small Cell Lung Cancer [IMpower132]

A PHASE III,OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB (MPDL3280A, ANTI-PD-L1 ANTIBODY) IN COMBINATION WITH CARBOPLATIN OR CISPLATIN+PEMETREXED COMPARED WITH CARBOPLATIN OR CISPLATIN+PEMETREXED IN PATIENTS WHO ARE CHEMOTHERAPY-NAIVE AND HAVE STAGE IV NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT2080223142

Enrollment

568

Registered

2016-03-11

Start date

2016-07-22

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Non-Small Cell Lung Cancer

Interventions

investigational material(s) Generic name etc : Atezolizumab INN of investigational material : atezolizumab Therapeutic category code : 429 Other antitumor agents Dosage and Administration for Investig

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1 -Histologically or cytologically confirmed, treatment-naieve Stage IV non-squamous NSCLC -No prior treatment for Stage IV non-squamous NSCLC. -Measurable disease as defined by RECIST v1.1 -Adequate hematologic and end organ function

Exclusion criteria

Exclusion criteria: -Participants with a sensitizing mutation in the epidermal growth factor receptor (EGFR) gene or with an anaplastic lymphoma kinase (ALK) fusion oncogene -Active or untreated central nervous system (CNS) metastasis -Malignancies other than NSCLC within 5 years prior to randomization -Known tumor PD-L1 expression status from other clinical studies -History of certain autoimmune disease -History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis -History of allergic reactions to cisplatin, carboplatin, or other platinum-containing compounds -Prior treatment with CD137 agonists or immune checkpoint blockade therapies, anti-PD-1, and anti-PD-L1 therapeutic antibodies -Severe infection within 4 weeks prior to randomization -Significant history of cardiovascular disease

Design outcomes

Primary

Measure	Time frame
efficacy RECIST v1.1, Observation	—

Secondary

Measure	Time frame
efficacy pharmacokinetics safety RECIST v1.1, Observation	—

Countries

Asia except Japan, Europe, Japan, North America, Oceania, South America

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026